Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
← catalyst calendarNCT05624450 · readout in 442 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
3,527estimated
Sites
464
Countries
Argentina, Australia, Belgium +36
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-13 | actual | When the study began enrolling |
| Primary completion | 2027-11-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-04 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Viral Lung Infection and Acute Respiratory Failure
Interventions
- Drug: Tozorakimab — also filed as MEDI3506
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO)
measured by Day 28
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed